Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)

ACS Medicinal Chemistry Letters

Volumn 6, Issue 7, 2015, Pages 736-740

  Hoveyda, Hamid R ^a   Fraser, Graeme L ^a   Dutheuil, Guillaume ^a   El Bousmaqui, Mohamed ^a   Korac, Julien ^a   Lenoir, François ^a   Lapin, Alexey ^a   Noël, Sophie ^a  

^a Euroscreen SA   (Belgium)

Author keywords

FSH; GnRH; LH; neurokinin B; NK3 antagonist; triazolopiperazine

Indexed keywords

LUTEINIZING HORMONE; NEUROKININ 3 RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISORDERS OF HORMONE METABOLISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; GONADAL DISEASE; HAPLORHINI; HYDROGEN BOND; HYPOTHALAMUS; IC50; IN VITRO STUDY; LIPOPHILICITY; LOSS OF FUNCTION MUTATION; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; UNBOUND FRACTION;

RATTUS;

EID: 84936883323     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00117     Document Type: Article

References (18)

1. Hoveyda, H. R.; Fraser, G. L.; Roy, M.-O.; Dutheuil, G.; Batt, F.; El Bousmaqui, K. J.; Lenoir, F.; Lapin, A.; Noël, S.; Blanc, S. Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I) J. Med. Chem. 2015, 58, 3060-3082 (Cpds 1, 2, and 8 were reported in ref 1 as 3, 31, and 39, respectively.)
2. Dawson, L. A.; Porter, R. A. Progress in the development of neurokinin 3 modulators for the treatment of schizophrenia: molecule development and clinical progress Future Med. Chem. 2013, 5, 1525-1546 and references therein
3. For a recent review, see: Skorupskaite, K.; George, J. T.; Anderson, R. A. The kisspeptin-GnRH pathway in human reproductive health and disease Hum. Reprod. Update 2014, 0, 1-16
4. Marshall, J. C.; Griffin, M. L. The role of changing pulse frequency in the regulation of ovulation Hum. Reprod. 1993, 8, 57-61
5. Francou, B.; Bouligand, J.; Voican, A.; Amazit, L.; Trabado, S.; Fagart, J.; Meduri, G.; Brailly-Tabard, S.; Chanson, P.; Lecomte, P.; Guiochon-Mantel, A.; Young, J. Normosomic congenital hypogonadotropic hypogonadism due to TAC3/TACR3 mutations: characterization of neuroendocrine phenotypes and novel mutations PLoS One 2011, 6, e25614
6. Fraser, G. L.; Hoveyda, H. R.; Clarke, I. J.; Ramaswamy, S.; Plant, T. M.; Rose, C.; Millar, R. P. The NK3 receptor antagonist ESN364 interrupts pulsatile LH secretion and moderates levels of ovarian hormones throughout the menstrual cycle. Endocrinology, submitted for publication.
7. Riggs, M. M.; Bennets, M.; van der Graaf, P. H.; Martin, S. W. Integrated pharmacometrics and systems pharmacology model-based analysis to guide GnRH modulator development for management of endometriosis CPT: Pharmacometrics Syst. Pharmacol. 2012, 1, e11
8. Millar, R. P.; Newton, C. L. Current and future applications of GnRH, kisspeptin and neurokinin B analogues Nat. Rev. Endocrinol. 2013, 9, 451-466 and references therein
9. Hopkins, A. L.; Keserü, G. M.; Lesson, P. D.; Rees, D. C.; Reynolds, C. H. The role of ligand efficiency metrics in drug discovery Nat. Rev. Drug Discovery 2014, 13, 105-121 and references therein
10. Leeson, P. D.; Empfield, J. R. Reducing the risk of drug attrition associated with physicochemical properties Annu. Rep. Med. Chem. 2010, 45, 381-391 and references therein
11. Lovering, F.; Bikker, J.; Humblet, C. Escape from flatland: increasing saturation as an approach to improving clinical success J. Med. Chem. 2009, 52, 6752-6756
12. Kalgutkar, A. S.; Driscoll, J.; Zhao, S. X.; Walker, G. S.; Shepard, R. M.; Soglia, J. R.; Atherton, J.; Yu, L.; Mutlib, A. E.; Munchhof, M. J.; Reiter, L. A.; Jones, C. S.; Doty, J. L.; Trevena, K. A.; Shaffer, C. L.; Ripp, S. L. A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif Chem. Res. Toxicol. 2007, 20, 1954-1965
13. Gramec, D.; Mašič, L. P.; Dolenc, M. S. Bioactivation potential of thiophene-containing drugs Chem. Res. Toxicol. 2014, 27, 1344-1358 and references therein
14. Trainor, G. L. The importance of plasma protein binding in drug discovery Expert Opin. Drug Discovery 2007, 2, 51-64 and references therein
15. Morita, S.; Miyata, S. Accessibility of low-molecular-mass molecules to the median eminence and arcuate hypothalamic nucleus of adult mouse Cell Biochem. Funct. 2013, 3, 668-677
16. Kratochwil, N. A.; Huber, W.; Muller, F.; Kansy, M.; Gerber, P. R. Predicting plasma protein binding of drugs: a new approach Biochem. Pharmacol. 2002, 64, 1355-1374
17. Kerns, E. H.; Di, L. Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization; Elsevier: Burlington, MA, 2008; pp 112-116.
18. For example, see: Godbole, A. M.; Ramalingam, S.; Ramamurthy, V. P.; Khandelwal, A.; Bruno, R. D.; Upreti, V. V.; Gediya, L. K.; Purushottamachar, P.; Mbatia, H. W.; Addya, S.; Ambulos, N.; Njar, V. C. O. VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague-Dawley rats Eur. J. Pharmacol. 2014, 734, 98-104 and references therein